source
- SonoThera secures $186 million to advance non-viral gene-therapy platformSonoThera, the winner of the Endpoints 11 2026 competition, announced a fresh financing round to push its non-viral gene-therapy technology forward. The company raised a total of $186 million, wit…
- Novo signs €1.2 bn deal with Nanexa for long-acting injectables as Acadia’s Alzheimer trial misses targetNovo has agreed to pay Nanexa up to about €1.165 bn for its PharmaShell delivery platform, which enables long-acting injectable medicines. The partnership will apply the technology to up to five c…